TB-500: what Thymosin Beta-4 is and why it matters

A synthetic fragment of a naturally occurring protein found in virtually every cell of the body — with a broad body of tissue-repair preclinical research.

TL;DR

• TB-500 is a synthetic peptide based on a fragment of Thymosin Beta-4 (Tβ4), a 43-amino-acid protein that occurs naturally in nearly every cell type in the human body.
• Thymosin Beta-4's primary cellular function is regulating actin — the protein that gives cells their structure and the ability to move and reshape themselves. This actin-binding role underlies most of the proposed biological effects.
• Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.

What it is

Thymosin Beta-4 is abundant in human cells. It was first identified in the thymus gland — hence the name — but has since been characterized as ubiquitous in cell types throughout the body, with particularly high concentrations in white blood cells, platelets, and tissues undergoing repair (Goldstein et al., Annals of the New York Academy of Sciences, 2012). TB-500, the form most commonly discussed online, is a synthetic fragment based on a biologically active sequence within full-length Thymosin Beta-4.

How it differs from full Thymosin Beta-4

The full-length Thymosin Beta-4 protein is 43 amino acids long. TB-500 corresponds to a shorter synthesized sequence drawn from that protein. The two molecules are related and share much of the proposed biology, but they are not identical, and the term "TB-500" in online discussion refers to the synthetic form specifically. Most of the published preclinical literature uses recombinant or synthetic Thymosin Beta-4 (or its fragments), so applying it to TB-500 adds a layer of uncertainty.

Who asks about it

People come to this topic when they have heard TB-500 mentioned in a tissue-repair or recovery context — often mentioned alongside BPC-157 — and want to understand what the peptide actually is. They also ask when they want to know where TB-500 stands with FDA in 2026.

What the research says

The research base for Thymosin Beta-4 and TB-500 spans cell biology, tissue repair, cardiac injury, and dermal wound healing (Crockford et al., Annals of the New York Academy of Sciences, 2010). The actin-binding mechanism is well characterized at the molecular level. Whole-organism preclinical research is substantial. Robust randomized human clinical trials are limited.

What to know

Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action.

The Halftime POV

TB-500's biology is genuinely interesting — actin regulation is one of the more fundamental processes in cell biology, so a peptide that influences it is a plausible research target for tissue repair. The honest framing is that the molecular biology is well characterized, and the human clinical trial base is still limited.

Related reading:

• How TB-500 works: actin regulation and tissue signaling
• TB-500 regulatory status: Category 2 and the path forward
• Category 1 vs Category 2 peptides: the regulatory framework

FAQ

Q: What is TB-500? A: TB-500 is a synthetic fragment of Thymosin Beta-4, a naturally occurring 43-amino-acid protein found in nearly every cell type in the body. The 'TB-500' designation refers to a specific synthesized peptide sequence corresponding to a biologically active region of full-length Thymosin Beta-4.

Q: Is TB-500 the same as Thymosin Beta-4? A: Not quite. Thymosin Beta-4 is the full naturally occurring 43-amino-acid protein. TB-500 is a synthetic fragment based on a portion of that sequence. They are related and share much of the proposed biology, but the molecules are not identical, and most of the popular discussion uses 'TB-500' to refer specifically to the synthetic form.

Q: What is the regulatory status of TB-500? A: TB-500 was placed in FDA Category 2 in 2023. FDA removed TB-500 from Category 2 on April 22, 2026, after its nomination was withdrawn. As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness.

Disclaimer

As of September 2026, FDA has not made a final decision on TB-500. At its July 23–24, 2026 meeting, FDA's Pharmacy Compounding Advisory Committee voted 8 yes, 6 no, and 1 abstention to recommend adding TB-500 to the Section 503A bulk drug substances list. The committee is advisory, and formal addition to the list requires further FDA action. This article is educational only and is not medical advice. Compounded medications are not FDA-approved.

Sources

• Goldstein AL, et al. Thymosin β4: a multi-functional regenerative peptide. Annals of the New York Academy of Sciences, 2012.
• Crockford D, et al. Thymosin β4: structure, function, and biological properties supporting current and future clinical applications. Annals of the New York Academy of Sciences, 2010.

This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). Compounded drugs are not FDA-approved and have not been evaluated by FDA for safety or effectiveness. This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.